In a nutshell This trial was carried out to examine the long-term safety and effectiveness of daratumumab (Darzalex) plus bortezomib (Velcade) and dexamethasone (Dexasone) in patients with previously treated multiple myeloma (MM). The authors concluded that after 3-years this treatment maintained benefit and...
Read More
In a nutshell This study compared the effectiveness of Kd (carfilzomib, dexamethasone) chemotherapy to Vd (bortezomib, dexamethasone) chemotherapy in patients with multiple myeloma (MM). This study found that Kd improved survival outcomes and had fewer side effects compared to Vd chemotherapy for these patients. Some background Multiple...
Read More
In a nutshell This study evaluated isatuximab, pomalidomide (Imnovid) and dexamethasone (Decadron) for recurrent or non-responsive multiple myeloma (MM). This study concluded that this treatment combination was safe and effective for these patients. Some background There are several treatment options for patients with MM. Most initial...
Read More
In a nutshell This study investigated the safety and effectiveness of a new chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study found that this cell therapy was effective, but it had significant side effects. Some background MM is a type of cancer of the...
Read More
In a nutshell This article investigated the safety and effectiveness of combining ixazomib (Ninlaro), cyclophosphamide (Cytoxan) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the combination treatment is safe and gave...
Read More
In a nutshell This article investigated the safety and effectiveness of adding daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the addition of daratumumab is safe and...
Read More
In a nutshell This study investigated the cardiovascular (heart and blood vessels) safety of carfilzomib (Kyprolis) in patients with relapsed or refractory (does not respond to treatment) multiple myeloma. This study concluded that the benefits of carfilzomib outweighed its risks. Some background Multiple myeloma is a type of cancer of the bone...
Read MoreIn a nutshell This study examined the effect of lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma. This study concluded that the treatment combination was effective and results were similar to that seen in clinical trials. Some background Lenalidomide is a type of immunotherapy (stimulates the immune system to fight...
Read MoreIn a nutshell This paper compared the effect of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Ozurdex) to lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. The addition of carfilzomib was associated with a longer survival. Some background Multiple myeloma is a cancer of the...
Read More
